External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter study.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
11 2020
Historique:
received: 16 02 2020
revised: 08 04 2020
accepted: 11 04 2020
pubmed: 30 5 2020
medline: 13 8 2021
entrez: 30 5 2020
Statut: ppublish

Résumé

To validate a nomogram predicting lymph node invasion (LNI) in prostate cancer patients undergoing radical prostatectomy taking into consideration multiparametric-magnetic resonance imaging (mp-MRI) parameters and targeted biopsies in a western European cohort. A total of 473 men diagnosed by targeted biopsies, using software-based MRI-ultrasound image fusion system, and operated by radical prostatectomy with extended pelvic lymph node dissection across 11 Europeans centers between 2012 and 2019 were identified. Area under the curve of the receiver operator characteristic curve, calibration plot and decision curve analysis were used to evaluated the performance of the model. Overall, 56 (11.8%) patients had LNI on final pathologic examination with a median (IQR) of 13 (9-18) resected nodes. Significant differences (all P < 0.05) were found between patients with and without LNI in terms of preoperative PSA, clinical stage at DRE and mp-MRI, maximum diameter of the index lesion, PI-RADS score, Grade Group on systematic and targeted biopsies, total number of dissected lymph nodes, final pathologic staging and Grade Group. External validation of the prediction model showed a good accuracy with an area under the curve calculated as 0.8 (CI 95% 0.75-0.86). Graphic analysis of calibration plot and decision curve analysis showed a slight underestimation for predictive probability for LNI between 3% and 22% and a high net benefit. A cut-off at 7% was associated with a risk of missing LNI in 2.6%, avoiding unnecessary surgeries in 55.9%. We report an external validation of the nomogram predicting LNI in patients treated with extended pelvic lymph node dissection in a western European cohort and a cut-off at 7% seems appropriate.

Identifiants

pubmed: 32466877
pii: S1078-1439(20)30152-6
doi: 10.1016/j.urolonc.2020.04.011
pii:
doi:

Types de publication

Journal Article Multicenter Study Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

847.e9-847.e16

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Romain Diamand (R)

Urology Department, Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: romain.diamand@erasme.ulb.ac.be.

Marco Oderda (M)

Urology Department, Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.

Simone Albisinni (S)

Urology Department, Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Brussels, Belgium.

Alexandre Fourcade (A)

Urology Department, Hôpital Cavale Blanche, CHRU Brest, Brest, France.

Georges Fournier (G)

Urology Department, Hôpital Cavale Blanche, CHRU Brest, Brest, France.

Daniel Benamran (D)

Urology Department, Hôpitaux Universitaires de Genève, Geneva, Switzerland.

Christophe Iselin (C)

Urology Department, Hôpitaux Universitaires de Genève, Geneva, Switzerland.

Gaelle Fiard (G)

Urology Department, CHU de Grenoble, Grenoble, France.

Jean-Luc Descotes (JL)

Urology Department, CHU de Grenoble, Grenoble, France.

Grégoire Assenmacher (G)

Urology Department, Jules Bordet Institute, Brussels, Belgium.

Ilyas Svistakov (I)

Urology Department, Jules Bordet Institute, Brussels, Belgium.

Alexandre Peltier (A)

Urology Department, Jules Bordet Institute, Brussels, Belgium.

Giuseppe Simone (G)

Urology Department, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.

Giacomo Di Cosmo (G)

Urology Department, Clinique Saint-Augustin, Bordeaux, France.

Jean-Baptiste Roche (JB)

Urology Department, Clinique Saint-Augustin, Bordeaux, France.

Jean-Louis Bonnal (JL)

Urology Department, Hôpital Saint-Philibert, GHICL, Lille, France.

Julien Van Damme (J)

Urology Department, University Clinics Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.

Maxime Rossi (M)

Urology Department, Clinique du Pré, Le Mans, France.

Eric Mandron (E)

Urology Department, Clinique du Pré, Le Mans, France.

Paolo Gontero (P)

Urology Department, Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.

Thierry Roumeguère (T)

Urology Department, Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH